Arovella Therapeutics - Q3 trading update confirms pipeline progression
Arovella’s Q322 trading update confirms the progress of its development pipeline, with an emphasis on its lead asset, ALA-101. With the selection of a contract manufacturing organisation (CMO; production of the plasmid and lentiviral vector for ALA-101 began in January 2022) and signed service agreement with Q-Gen Cell Therapeutics (to manufacture CAR-iNKT cells), the company is progressing towards clinical development. Separately, Arovella secured a US patent for the oral spray formulation of anagrelide, which is under development and should expand the market opportunity for the drug and supplement its existing patents in Europe, Japan and Australia. At the end of Q322, cash stood at A$8.1m, benefiting from funding activity during the quarter.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.